For many people with PTSD, going to sleep doesn’t necessarily mean escaping the trauma. Nightmares can bring it back night after night, sometimes vividly enough to wake someone in panic and make sleep itself something to fear.
These nightmares are remarkably common. An estimated 50% to 70% of people with PTSD experience recurrent nightmares, often during REM sleep, when dreaming is most vivid. Repeatedly losing sleep can create problems that extend well into the following day, affecting concentration, mood, emotional regulation, and potentially making it harder to cope with other symptoms of PTSD.
Despite how disruptive these nightmares can be, treating them isn’t always straightforward. That has researchers exploring some unexpected possibilities, including a medication better known for an entirely different purpose.
In August 2026, researchers at Charité-Universitätsmedizin Berlin published the results of a randomized controlled trial in Nature Medicine examining dronabinol, a prescription medication containing synthetic THC that is more commonly used to treat nausea and vomiting associated with chemotherapy.
Over 10 weeks, the researchers tested whether the drug could reduce trauma-related nightmares in people with PTSD. The results were striking: patients receiving dronabinol experienced a greater reduction in nightmare severity than those given a placebo, and more than a third reported that their nightmares had disappeared entirely by the end of treatment.
But perhaps the more interesting part of the research is why it may have worked. Rather than simply sedating patients or dulling their dreams, the researchers believe dronabinol may be influencing the way the sleeping brain processes fear and emotional memories, offering a potential clue to why traumatic experiences can continue resurfacing long after someone falls asleep.
Why cannabis PTSD nightmares research has been so difficult
The gap between what patients report anecdotally and what clinical trials have proven has long been a problem in cannabis research. People with PTSD, particularly veterans, have used cannabis informally for years to manage sleep. Earlier reviews of the evidence found that while cannabinoids showed some promise for reducing nightmares and improving sleep, the available study designs at the time could not support clinical recommendations about routine use. What was missing was a large, properly controlled trial with enough participants to produce results that clinicians could rely on.
The challenge of designing such a trial is real. Nightmares are subjective. Placebo responses in sleep and distress studies tend to be large. Because THC has a distinctive psychoactive effect, blinding participants convincingly is difficult. The Berlin team addressed that problem directly: participants split roughly in half, with 87 receiving dronabinol and 84 receiving a placebo designed to look, taste, and smell identical, including a cannabis flavoring so that taste alone would not give away the assignment.
What dronabinol actually is
Dronabinol is a pharmaceutical form of THC delivered as oil drops. It is a controlled prescription medication approved by the FDA in 1985 for chemotherapy-induced nausea and HIV/AIDS-related anorexia, and it has been available in the U.S. and Germany for decades. Using it for PTSD nightmares is an off-label application, but the pharmacological rationale is grounded in how the brain manages fear during sleep.
THC acts on the body’s endocannabinoid system, a signaling network that helps regulate stress responses, mood, memory consolidation, and sleep architecture. REM sleep – the phase when the most vivid dreaming occurs – is also when the brain attempts to process and file emotional memories. In people with PTSD, that process misfires: the brain replays trauma without resolving it, which is why nightmares recur night after night. THC appears to dampen the intensity of REM sleep activity, reducing the conditions that allow traumatic dreams to replay with such vividness.
The trial design and results
The trial enrolled 171 adults with PTSD and frequent severe nightmares across four German university medical centers: Charité-Universitätsmedizin Berlin, the Psychiatric University Clinic of the Charité at St. Hedwig Hospital, the University Medical Center Hamburg-Eppendorf, and the Central Institute for Mental Health in Mannheim. The four-center, double-blind, placebo-controlled design makes this among the most methodologically rigorous cannabis studies conducted in the psychiatric field.
Doses were raised over the first four weeks, from 2.5 to 15 milligrams a day, taken once daily as oil drops before bed, then held steady for six more weeks. The titration approach mirrors the careful dose management used in other psychiatric medications and is designed to minimize side effects while finding each patient’s effective dose.
After ten weeks, nightmare burden – measured on a scale from zero to eight points – had fallen by an average of 3.7 points in the dronabinol group, compared with 2.2 points in the placebo group. More than a third of patients treated with dronabinol reported that their nightmares had disappeared entirely by the end of the study. An additional 21% reported that their nightmare burden had fallen by at least half. About five out of six patients in the dronabinol group also reported a noticeable improvement in their overall health.
What dronabinol did not do
The study’s positive results come with an important qualification. Dronabinol did not clearly reduce overall PTSD severity or the depression that often accompanies the disorder. The researchers noted that long-term efficacy and safety require further evaluation. In clinical terms, the drug functions as a targeted nighttime intervention rather than a comprehensive PTSD treatment.
The two medications currently approved by the FDA specifically for PTSD are sertraline and paroxetine. Prazosin, approved for hypertension, has also been used off-label for PTSD-related nightmares and hyperarousal. Psychological therapies including cognitive processing therapy and prolonged exposure therapy remain the foundation of PTSD care, and improved sleep could make patients more able to engage with them. Based on this trial’s data, dronabinol would be additive to existing approaches rather than a replacement.
The safety picture
No severe adverse effects were reported in the trial. Mild effects that occurred more often in the dronabinol group included dizziness, headaches, and increased appetite. The percentage of participants who discontinued treatment due to adverse events was actually lower in the dronabinol group than in the placebo group.
Participants reported no meaningful withdrawal symptoms after stopping dronabinol at the end of the 10-week study. The researchers are appropriately cautious about this finding: ten weeks is not long enough to establish a long-term safety profile. Tolerance, dependence, and the effects of extended use all remain open questions that future trials will need to address.
Where the research goes from here
The researchers described their findings as extending preliminary open-label and retrospective studies, providing the first evidence from an appropriately powered randomized controlled trial that cannabinoid receptor agonists improve PTSD-related nightmares. Previous cannabis-and-PTSD studies were mostly small, retrospective, or lacked placebo controls. Publication in Nature Medicine reflects the methodological step forward this trial represents.
The Charité team has indicated that data analysis will continue. Dronabinol is already available in Germany, though it is not approved for this specific indication in the U.S. Any path toward FDA approval for PTSD nightmares would require additional trials, likely including longer follow-up periods, broader demographic representation, and comparisons with other off-label options currently in use.
Read More: Sleep Paralysis Explained: Why the Body Freezes While the Mind Wakes
What this means for you
If you or someone you care about lives with PTSD and is struggling specifically with nightmares that have not responded to antidepressants or talk therapy, this research opens a credible avenue worth discussing with a doctor. Dronabinol is a controlled prescription medicine, not an over-the-counter supplement, and using it requires careful dose management under medical supervision. The trial’s starting dose of 2.5 milligrams, titrated slowly over four weeks, reflects how precisely that management needs to be handled.
Cannabis products purchased outside a clinical or pharmacy setting are not equivalent to dronabinol. They are not standardized, not dosed reliably, and have not undergone the same safety assessment. The trial’s positive findings apply specifically to a regulated pharmaceutical form of THC administered under controlled conditions. For anyone currently under PTSD care, the most practical step is to ask a prescribing clinician whether dronabinol might be appropriate and what the evidence looks like for their specific situation.
Disclaimer: The information provided here is for educational and informational purposes only and is not a substitute for professional psychological, psychiatric, or mental health advice, diagnosis, or treatment. Always seek the guidance of a licensed mental health professional, therapist, psychologist, or psychiatrist with any questions or concerns about your emotional well-being or mental health conditions. Never ignore professional advice or delay seeking support because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: LSD Research Leads Scientists to Unexpected Brain-Drug Breakthrough